[go: up one dir, main page]

AR087380A1 - Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas - Google Patents

Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas

Info

Publication number
AR087380A1
AR087380A1 ARP120102767A ARP120102767A AR087380A1 AR 087380 A1 AR087380 A1 AR 087380A1 AR P120102767 A ARP120102767 A AR P120102767A AR P120102767 A ARP120102767 A AR P120102767A AR 087380 A1 AR087380 A1 AR 087380A1
Authority
AR
Argentina
Prior art keywords
dendritic cell
pancreatic cancer
cancer therapy
pancreas cancer
cell vaccines
Prior art date
Application number
ARP120102767A
Other languages
English (en)
Inventor
Anna Karolina Palucka
Jacques F Banchereau
Hideki Ueno
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of AR087380A1 publication Critical patent/AR087380A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones y métodos para obtener inmunidad terapéutica y mejorar el estado clínico en pacientes de cáncer de páncreas. Se describe una vacuna de células dendríticas (CD) pulsadas por péptidos derivados de antígenos de cáncer pancreático para la terapia contra el cáncer de páncreas. La vacuna que se describe produce la expansión de células T específicas del cáncer en pacientes con cáncer de páncreas. Células presentadoras de antígenos (APC) y uso.
ARP120102767A 2011-07-27 2012-07-27 Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas AR087380A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161512233P 2011-07-27 2011-07-27

Publications (1)

Publication Number Publication Date
AR087380A1 true AR087380A1 (es) 2014-03-19

Family

ID=47597383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102767A AR087380A1 (es) 2011-07-27 2012-07-27 Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas

Country Status (9)

Country Link
US (1) US20130028915A1 (es)
EP (1) EP2736527A4 (es)
JP (1) JP2014521657A (es)
KR (1) KR20140054140A (es)
AR (1) AR087380A1 (es)
AU (1) AU2012286690A1 (es)
CA (1) CA2843200A1 (es)
TW (1) TW201311895A (es)
WO (1) WO2013016675A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5971945B2 (ja) 2008-04-17 2016-08-17 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ カチオン性脂質の鏡像異性体による免疫応答の刺激
KR20150058139A (ko) 2012-06-15 2015-05-28 피디에스 바이오테크놀러지 코퍼레이션 양이온성 지질 백신 조성물 및 이용 방법
WO2014047533A1 (en) 2012-09-21 2014-03-27 Frank Bedu-Addo Improved vaccine compositions and methods of use
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2014127276A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods
IN2013MU02876A (es) * 2014-03-04 2015-09-25 Upadhyay Shakti
WO2016014613A1 (en) 2014-07-22 2016-01-28 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
MX2018008797A (es) 2016-01-19 2018-11-29 Pfizer Vacunas contra el cancer.
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
EP3658158A4 (en) * 2017-07-27 2021-04-14 The National Institute for Biotechnology in the Negev Ltd. SMAC / YLDIABLO INHIBITORS TO TREAT CANCER
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
JP2021013301A (ja) * 2017-10-20 2021-02-12 公立大学法人和歌山県立医科大学 メソテリン由来のｈｌａ−ａ２４拘束性エピトープペプチド
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE254931T1 (de) * 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
EP1575500A4 (en) * 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP2037957A4 (en) * 2006-06-30 2010-09-08 Baylor Res Inst USING GM-CSF AND INTERFERON ALPHA PRODUCED AND DENDRITIC CELLS LOADED WITH HEAT-TREATED AND DEFECTED CANCER CELLS
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2025746A1 (en) * 2007-08-16 2009-02-18 Cell Med Research GMBH Dendritic cells
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体

Also Published As

Publication number Publication date
EP2736527A4 (en) 2015-01-07
TW201311895A (zh) 2013-03-16
WO2013016675A1 (en) 2013-01-31
AU2012286690A1 (en) 2014-03-06
US20130028915A1 (en) 2013-01-31
CA2843200A1 (en) 2013-01-31
JP2014521657A (ja) 2014-08-28
EP2736527A1 (en) 2014-06-04
KR20140054140A (ko) 2014-05-08

Similar Documents

Publication Publication Date Title
AR087380A1 (es) Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
MX2017008487A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
AR088820A1 (es) Moleculas de anticuerpo que tienen especificidad por ox40 humano
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
AR078693A1 (es) Vacunas dirigidas contra celulas presentadoras de antigenos
AR109707A1 (es) Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
BR112013029834A2 (pt) vacinas individualizadas para câncer
EA201301089A1 (ru) Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток
MX2015010783A (es) Composicion de vacuna.
MX2016014099A (es) Productos de esmalte y metodos de uso.
BR112016014488A2 (pt) Meio para cultura celular
MX2018010616A (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
GT201500249A (es) Terapia de combinación
CL2015001900A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina.
AR080111A1 (es) Metodos y composiciones de inmunizacion
AR088220A1 (es) Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma
MX384875B (es) Método para obtener una vacuna de mycoplasma.
EP4316497A3 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
MX2016007726A (es) Inmunoterapia de cancer mediante el suministro de antigenos mhc clase ii usando un replicon de vlp.

Legal Events

Date Code Title Description
FB Suspension of granting procedure